Latest Strategy News

Island Pharmaceuticals reports a 213.8% increase in half-year loss to $4.81 million, driven by strategic acquisition and clinical development investments. The company advances its antiviral portfolio with Galidesivir and ISLA-101, supported by strong US regulatory engagement and a $9 million capital raise.

Oliver’s Real Food Limited has reported a statutory net profit after tax of $995,000 for the half-year ended December 2025, marking a $1.82 million turnaround from the previous loss. This improvement comes despite a 6.5% revenue decline, driven by strategic store closures and disciplined cost management.

Global Health Limited reports a modest half-year loss reduction alongside a steady rise in recurring SaaS revenue, signaling progress in its digital healthcare transformation.

RocketDNA Ltd reported a 6% increase in revenue to AUD 76.83 million for the year ended 31 December 2025, expanding its autonomous drone footprint across Australia and Africa while securing major mining contracts.

Vitura Health Limited reported an 8.3% rise in half-year revenues to $67.87 million, driven by medicinal cannabis sales and telehealth services, yet posted a consolidated loss of $986,341 due to margin pressures and increased costs. Leadership changes and strategic investments mark a pivotal phase for the digital health and medicinal cannabis player.

HITIQ Limited reported a $2.9 million loss for the half-year ending December 2025, while making significant strides in international market expansion and strategic partnerships. The company’s capital raising efforts aim to support its transition from technology validation to commercial execution.

Acorn Capital Investment Fund Limited has reported a remarkable half-year performance for the period ending 31 December 2025, with revenue and profit soaring over 300%. The fund also declared a fully franked interim dividend of 3.5 cents per share, signalling confidence in its investment strategy.

Stealth Group Holdings has delivered record half-year results for 1H26, boosted by its strategic acquisition of Hardware & Building Traders and a strengthened balance sheet. The company is now targeting over $500 million in sales by FY28, signalling ambitious growth in Australia's fragmented hardware and industrial distribution market.

MA Credit Income Trust reported a strong half-year profit of $19.7 million, exceeding its return target, while successfully completing a $190.5 million capital raise and initiating a strategic buy-back to manage liquidity.

Imugene Limited reports a narrower half-year loss as it advances its promising azer-cel CAR T therapy with strong clinical results and FDA backing, supported by a $25 million capital raise.

Regal Investment Fund reported a remarkable half-year performance with a 201% increase in operating profit and a 12 cents per unit distribution declared for December 2025. The Fund's strategic buy-back program and strong net asset growth underscore its robust position.

Dominion Income Trust 1 has reported a robust $12.3 million profit and paid distributions totaling 359.41 cents per unit in its inaugural half-year ending December 2025. The Trust outperformed its benchmark, signalling a promising start for investors.